Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967786 | 1.00 | ALOX15 (0.71) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL4447132 | 0.91 | ALOX15 (0.67) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL29216408 | 0.91 | ALOX15 (0.67) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL24968077 | 0.88 | KMT2A (0.59) | ALOX15ALDH1A1MEN1CYP3A4KMT2A | |
| SCHEMBL20610548 | 0.88 | KMT2A (0.59) | ALOX15ALDH1A1MEN1CYP3A4KMT2A | |
| SCHEMBL2425212 | 0.88 | KMT2A (0.59) | ALOX15ALDH1A1MEN1CYP3A4KMT2A | |
| SCHEMBL2425211 | 0.88 | KMT2A (0.59) | ALOX15ALDH1A1MEN1CYP3A4KMT2A | |
| Citronellol SCHEMBL18301310 | 0.83 | ALOX15 (1.00) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| Citronellol SCHEMBL1871004 | 0.83 | ALOX15 (1.00) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| Citronellol SCHEMBL21320 | 0.83 | ALOX15 (1.00) | ALOX15ALDH1A1TSHRUSP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021002821-A1 | A METHOD FOR OBTAINING SAPONIN MOLECULES AND UTILIZING ACTIVE MOLECULES AS IMMUNOMODULATOR | İZMİR YÜKSEK TEKNOLOJİ ENSTİTÜSÜ (TR) | 2021-01-07 | — | — | WO | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | disclosed |
| US-20240410055-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| US-20240376038-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING HYDROXYMELONAL FORMATE ESTER | P2 SCIENCE INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240277012-A1 | DUPLICATE BEVERAGE | WANG JIE (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2023213310-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2023-11-09 | — | — | WO | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| CN-112567013-B | Benefit agent delivery particles | 联合利华知识产权控股有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2023057401-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-20080176781-A1 | Perfumes for linear citrus release in rinse-off systems | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2008-07-24 | — | — | US | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1390337-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | Givaudan SA (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096850-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | disclosed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-5231232-A | Method of preparing C-18 ketones used in the manufacture of Vitamins E and K | LOYOLA UNIVERSITY OF CHICAGO (US) | 1993-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | ALOX15 3088/4885ALDH1A1 978/4885TSHR 3246/4885 |
| US-20240376038-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING HYDROXYMELONAL FORMATE ESTER | ADH5, HTR5A, FAAH | ALOX15 144/4885ALDH1A1 206/4885TSHR 3840/4885 |
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | ALOX15 2929/4885ALDH1A1 658/4885TSHR 4237/4885 |
| US-20040171516-A1 | Precursors for ketones and aldehydes | PDK3, PDK4, AKR1C4 | ALOX15 513/4885ALDH1A1 13/4885TSHR 4789/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | ALOX15 3088/4885ALDH1A1 978/4885TSHR 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.